10-Q: Intelligent Bio Solutions Inc. Reports Increased Revenue but Continues to Face Losses in Q1 2025

Intelligent Bio Solutions Inc. saw a revenue increase in the first quarter of 2025, but ongoing research and development costs contributed to a net loss.

Summary

• Intelligent Bio Solutions Inc. reported a revenue of $872,287 for the three months ended September 30, 2024, compared to $796,094 for the same period in 2023.
• The company's gross profit increased to $346,801 from $232,331 year-over-year, driven by higher sales and improved production capacity.
• However, the company experienced a net loss of $2,694,799, compared to a net loss of $2,432,424 in the prior year, primarily due to increased development and regulatory expenses.
• Operating expenses totaled $3,198,190, which included significant investments in development and regulatory approval expenses, particularly related to the FDA 510(k) clinical study plan.
• The company's cash and cash equivalents stood at $3,989,431 as of September 30, 2024, with a working capital of $800,112.
• The company has raised $34,511 through an at-the-market offering of shares.
• Management has expressed concerns about the company's ability to continue as a going concern due to ongoing losses and the need for additional funding.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth and clinical progress offset by significant losses, going concern concerns, and a material weakness in internal controls. The need for additional capital raises further concerns.

Positives

• The company experienced a notable increase in revenue, indicating growing market acceptance of its products.
• Gross profit margin improved significantly, suggesting better cost management and pricing strategies.
• The successful completion of key clinical testing milestones for FDA approval is a positive step towards entering the US market.
• The expansion of the customer base and distribution network demonstrates the company's growing global reach.
• The company secured a new partnership to support its FDA 510(k) clinical study plan.

Negatives

• The company continues to incur significant net losses, raising concerns about its financial sustainability.
• Development and regulatory expenses have increased substantially, reflecting the high costs associated with regulatory approvals.
• The company's management has expressed concerns about its ability to continue as a going concern, indicating a need for additional funding.
• The company has a material weakness in internal control over financial reporting.

Risks

• The company's cash reserves may be insufficient to fund operations for the next twelve months.
• There is a risk that the company may not be able to raise additional capital on favorable terms, or at all.
• Failure to achieve milestones for the government grant could result in the need to refund the grant.
• The company has a material weakness in internal control over financial reporting.
• The company is in early-stage discussions regarding the potential restructuring of future licensing of BPT and products with the University of Newcastle, with no timeline established.

Future Outlook

The company anticipates operating losses for the foreseeable future and expects to continue incurring operating losses until it achieves regulatory approval in the US and other markets, expands its revenue base, and continues product development. The company expects development and regulatory expenses to increase in future periods as it continues its FDA 501(k) clinical study plan. The company plans to submit its FDA 510(k) application in the fourth quarter of this calendar year.

Management Comments

• Management believes there is material risk that the Company's cash and cash equivalents as of September 30, 2024, may be insufficient to fund its current operating plan through at least the next twelve months.
• Management is committed to continuing the steps necessary to remediate the control deficiencies that constituted the material weaknesses.

Industry Context

The company operates in the medical technology sector, focusing on non-invasive testing solutions. The need for rapid and accurate diagnostic tools is growing, and the company's focus on fingerprint-based drug screening and biosensor technology aligns with this trend. The company's expansion into new markets and partnerships with distributors are consistent with industry growth strategies.

Comparison to Industry Standards

• The company's revenue growth is positive, but its continued losses are a concern compared to established medical technology companies.
• Companies like Abbott Laboratories and Danaher Corporation, which are leaders in the diagnostics space, have significantly higher revenue and profitability.
• The company's focus on innovative technologies like fingerprint-based drug screening is comparable to other emerging companies in the point-of-care testing market, such as Senseonics and Livongo, but these companies have also faced challenges in achieving profitability.
• The company's reliance on external funding is typical for early-stage medical technology companies, but the need for additional capital raises concerns about its long-term financial stability.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential capital raises.
• Employees may be impacted by potential cost-cutting measures if the company's financial situation does not improve.
• Customers may be affected by potential delays in product development or service delivery.
• Creditors face increased risk due to the company's going concern issues.

Next Steps

• The company plans to submit its FDA 510(k) application in the fourth quarter of this calendar year.
• The company will continue to work on remediating the material weakness in internal control over financial reporting.
• The company will continue discussions regarding the potential restructuring of future licensing of BPT and products with the University of Newcastle.

Key Dates

Keywords

Intelligent Fingerprinting, Drug Screening, Biosensor Platform, FDA 510(k), Medical Technology, Point of Care Testing, Revenue, Net Loss, Clinical Study, Regulatory Approval